• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A three component-mixed vaccine against infections caused by Pseudomonas aeruginosa which comprises as the antigens an infection-protective common antigen OEP (Original Endotoxin Protein) obtained from P. aeruginosa, an elastase toxoid obtained from P. aeruginosa and a protease toxoid obtained from P. aeruginosa.
    公开号:SU784796A3
    申请号:SU772448254
    申请日:1977-02-04
    公开日:1980-11-30
    发明作者:Хомма Юзуру；Морихара Казуюки
    申请人:Сионоги Энд Ко, Лтд, Дзе Китасато Институт (Фирма)；
    IPC主号:
    专利说明:

    (54) METHOD OF OBTAINING; VACCINES AGAINST INFECTIONS, AND 13TH EXHAUSTABLE PSEUDOHONAS AERUGiNOSA
    one
    This invention relates to vaccine serum production.
    A known method for producing a vaccine against infections caused by Pseudomonas aerugtnosa, based on a natural endotoxin blue protein derived from Pseudomonas aeruginosa M.
    However, the vaccine obtained in a known manner does not have sufficiently high immunogenicity.
    The aim of the invention is to increase the immunogenic properties of the vaccine.
    This goal is achieved in that the natural endotoxin protein, Pseudomonas aeruginosa toxoid elastase and Pseudomonas aeruginosa toxon protease are dissolved in a solvent to a concentration of 0.1200 & 0 ml / 1-4000 iJ5 / ml and 14000 5 / ml, respectively, and are mixed. them in these concentrations under sterile conditions.
    In addition, distilled water, physiological saline or phosphate-buffered sodium chloride solution is used as a solvent.
    In order to extend the storage time
    the vaccine is administered antiseptic timorosal, phenol, carbolic acid or formalin ...
    The method is carried out as follows.
    5 Toxoid elastase is prepared from elastase by converting it to toxoid using the usual method of producing toxoids from protein toxins by treatment with formaldehyde or oxime tansulfinic acid.
    Pure elastase solution (containing 10–15 mg of enzyme protein per 1 ml (50 units of proteinase per 1 mg of enzyme protein), 5 moles of sodium chloride, 10 mmol of acetate
    sodium, 2 mmol calcium chloride. and 0.1 mmol zinc chloride), diluted with borate buffer (pp 9) to an enzyme concentration of 2-5 m1: / ml
    20 (the final concentration of borate is 0.1 M) and formalin is added to obtain a final concentration of 1% (volume ratio J.) The mixture is kept
    25 at room temperature. After one day, almost complete deactivation is achieved. The elastase solution deactivated in this way is dialyzed with water and lyophilized.
    30 to obtain toxoid.
    By the term proteinase unit as used herein is meant the activity of the protease, as determined by the following procedure.
    Casein (2% by volume, pH 7.4) (1 ml) is mixed with an appropriately diluted enzyme solution, and after completion of the reaction, a reaction stopping solution is immediately added to the solution for 10 minutes, containing 0.1 mol of trichloro: Uxusium acid, 0.2 mol of acetic acid and 0.2 mol of sodium acetate (2 ml). The mixture was kept at that temperature for 20 minutes until the unreacted casein was completely precipitated and then filtered. subjected to the determination of ty: rosin by the method of Folapna. Increase 1 unit. Tyrosine per minute indicates proteinase activity: equal to one.
    The physical and chemical properties of the toxoid elastae thus obtained are as follows.
    Molecular weight: 47,000 (gel filtration).
    Ultraviolet absorption spectrum: maximum 278 nm (21.2.0.1 M KC 2), minimum 252 nm.
    Isoelectric point: pH 6.5 (electrophoresis with acetate film).
    Appearance: colorless powder.
    Contains amino acid residues, g / 100 g protein: aspartic 14.2; threonine 5.0; proline 2.9 | glycine 5.6 alanine 5.8, valine 4.9, methionine 2., 9 isoleicin 2.7; leucine 3.9; tyrosine 9.9 / phenylalanine 7.0; lysine 3,9) histidine 2,6; arginine 6.5, cystin-2 1.20 tryptophan 2,3; ammonia 0.9, total 94.7 g
    No elastase activity is observed.
    Antigen activity is observed.
    The protease toxoid can be prepared from the protease by transferring it to a TOXOID by treatment with, for example, formaldehyde or hydroxymethanesulfinate in the presence of an amino acid.
    An example of producing a protease toxoid.
    Pseudomona aeruglfrosa protease crystals (100 mg) are dissolved in 0.1 MtpacTBOpe containing. 0.2 moles lysine (about 20 ml) and formalin is added to obtain a final concentration of 8% (volume ratio). The mixture is kept at room temperature for 3 or more days and 3 s is subjected to digestion with water and lyophil. to obtain toxoid.
    The physical and hicdastic properties of the protease toxoid thus obtained are as follows.
    Molecular weight: 63,000 (gel filtration).
    Ultraviolet absorption spectrum: maximum 280 nm (, ° 9.27, 0.1 M CO), minimum 250 nm.
    Isoelectric point: pH 5.2 (focal electrophoresis).
    Appearance: colorless powder.
    Contains amino acid residues, G / 100 g protein: aspartic 15.6; threonine 5.0, serine 7.6; glutamine 9.5, proline 2.1, glycine 7.7; alanine 8.5; valine 5, o; isoleucine 3.9; leucine 8.7; tyrosine 6.9; phenylalanine 5.9; lysine 4.1; histidine 1.9; arginine 2,3 | tryptophan 2,3; ammonia 1.4; only 98.5 g.
    No protease activity is observed.
    Antigen activity is observed.
    To obtain a vaccine, an infectious-protective normal antigen of natural endotoxin protein (NEL), toxoid elastase and toxoid protease are dissolved in a solvent in an optimal proportion. If necessary, the reinforcing effect of the additive and / or antiseptic can be added to the resulting solution.
    The solvent can be used any suitable for the preparation of vaccines for humans and animals, for example, distilled water, physiological sodium chloride solution, sodium chloride solution containing phosphate as a buffer, etc.
    The additive can be any conventional additive, for example, aluminum hydroxide, phosphate, calcium phosphate, alum or Freund's incomplete additive. The amount of additive can be chosen from the limit of quantities necessary and sufficient to increase immunization activity. Antiseptic can also be Conventional, for example, thimerosal, phenol or formalin.
    To increase the protective effect, the proportion of the components in the vaccine can be varied within effective amounts. The amount of each component varies significantly depending on the amount of immunization and on the interval between immunizations. It also varies with the purpose of the vaccine (i.e., prophylactic or therapeutic).
    The following are some examples of preferred doses and proportions of antigens.
    For man and also for cattle) ..
    When immunization is performed 2-3 times per week (without additive), the following proportions are preferred: NEB
    | 0.1-10 units per 1 kg of body weight toxoid protease 1-50 units. per 1 kg body weight; elastase toxoid 1-50 units per 1 kg of body weight. Depending on the amount of immunization, these amounts may be increased,
    Preventive vaccine.
    When immunization is carried out twice (using an additive), the following proportions of NEB 10-2000 units are preferred. on the head; toxoid protease 10-2000 units on the head, elastase toxoid 100-2000 units. on heads
    When immunization is performed once, the following proportions are recommended: NEB 500-2000 units. on the head, protease toxoid 500-4000 units. on the head, elastase toxoid 500-4000 units. on the head.
    Therapeutic vaccine.
    When immunization is carried out 2-3 times with an interval of one week (with or without the reinforcing additive, the following proportions are preferable: NEB 0.1-100 units per head / protease toxoid 10-2000 units per head; elastase toxoid 10-2000 units per head
    The vaccine can be administered to animals or humans intramuscularly or subcutaneously.
    The toxicity of each component in the vaccine is as follows.
    NEB: An injection into the peritoneum of a myoi dose of 100 mg / kg causes temporary asthenia, but the animal does not die. In the usual test with rabbits, a positive effect with a dose of 0.3 mg / kg is observed with regard to the properties of NEB to cause pyrection. The toxicity of NEB as endotoxic is very small compared to the toxicity of lipopolyosis (LP) and a mixture of NEB and LP.
    Toxoid elastase and toxoid protease. Intraperitoneally administering a dose of 1 mg per mouse to the mouse does not cause acute poisoning. The minimum lethal dose of protease is 0.2 mg per mouse weight, and the minimum lethal dose of elastase is 0.125 mg per mouse weight.
    When immunized with a vaccine, the effect of protection against infections caused by P. aeruginosa is significantly increased in comparison with immunization with a simple vaccine containing only NEB. Therefore, the vaccine is highly effective: for the prevention and treatment of infections caused by P. aeruginosa in animals and humans.
    Antibodies or serum containing antibodies that are obtained by inoculating a vaccine in animals and humans can be used to protect wounds (e.g. ulcers, corneas) from infections caused by Pseudomonas aeruginosa, and to treat them.
    Example 1. A solution of toxoid protease and potassium alum.
    The protease toxoid (100 mg) is dissolved in an aqueous solution of sodium chloride containing 24.8 ml of phosphate buffer (pH 7.4), and 25 ml of a 10% solution of potassium alum K2, Al2 (SO) is added. 2.5 ml of a 20% aqueous .12H20 solution was added to the resulting solution and the pH was adjusted to 6.5 to cause complete precipitation. A 1% solution of thimerosal (0.3 ml) is then added.
     as an antiseptic (1 mg protease toxoid per 0.3 ml).
    A solution of toxoid elastase and potassium alum. The solution is prepared in the same way as in the first case, but
    5 using elastase toxoid instead of protease toxoid.
    Solution {EB and potassium alum. NEB (100 mg) is dissolved in 0.01 n. NaOH solution (5 ml) and phosQa buffer (28 ml) are added. To the resulting solution, a 10% solution of potassium alum (3.3 ml) and a 20% solution (3.3 ml) are sequentially added, after which a 1% solution of thimerosal (0.4 ml) is added.
    Thus prepared solution of toxoid protease and aluminum alum, solution of toxoid elastase and aluminum alum and solution of NEB
    0 and aluminum alum just before use mix. 500 ml of this mixed solution contains 500 units. elastase toxoid, 500 units. protease toxoid and
    5 500 units NEB.
    Example 2. A solution of toxoid protease and aluminum hydroxide, a solution of toxoid elastase and aluminum hydroxide and a solution of NEB and hydroxide
    Aluminum 0 is prepared in the same manner as in Example 1, but using a 10% solution of aluminum hydroxide instead of a 10% solution of potassium alum.
    С The three solutions prepared in this way are mixed immediately before use.
    The resulting vaccine provides a much greater effect of protection against
    Q infections caused by P.aeruginosa in comparison with the usual vaccine containing only NEB.
    When using one NEB (group A), 205 means 3 or less. In differing from this in
    5 group B, immunized with a vaccine, ZOgQ exceeds 1.9 x Yu, and, therefore, it is significantly different from group A. In the untreated group, ZDgQ is 3.4. 10. Upon immunization
    0 JEB, the value of ZDgg usually from 100 to 1000 times increases the resistance to the number of live bacteria in comparison with the untreated group.
    When using the proposed
    5 vaccine containing toxoid protease
    and elastase toxin, in addition to NEB, immunized animals acquire resistance to the amount
    live bacteria in times larger in comparison with the untreated group (see table).
    权利要求:
    Claims (3)
    [1]
    Claim
    1. A method of obtaining a vaccine against infections caused by Pseudomonas aeruginosa based on a natural endotoxin protein obtained from Pseudomonas aeruginosa, characterized in that, in order to increase the immunogenic properties of the vaccine, the natural endotoxin protein, elastase toxoid from Pseudomonas aeruginosa and proteoid aerosinomonosa aeruginosa protease aeruginosa in a solvent up to a concentration of 2000¾. / ml, 1-4000¾ / ml and 1
    OD45
    I * · ·
    4000¾ / ml, respectively, and they are under these concentration conditions.
    [2]
    2. The method according to claim 1, such as using a distilled water, physiological saline or phosphate-buffered sodium chloride solution.
    [3]
    3. The method according to claim 1, with the fact that, in order to extend the shelf life, the antiseptic thimerosal, phenol, carbolic acid or formalin is introduced into the vaccine.
    类似技术:
    公开号 | 公开日 | 专利标题
    US3983229A|1976-09-28|Vaccines, the process for preparing the same and the applications thereof
    Pappenheimer Jr et al.1972|An immunological study of the diphtheria toxin molecule
    EP0073371B1|1985-11-21|Intravenously injectable immune serum globulin and method of preparing same
    US4075321A|1978-02-21|Vaccines, the process for preparing the same and the applications thereof
    SU784796A3|1980-11-30|Method of preparing vaccine for controlling pseudomonas acruginosa caused infections
    IE48402B1|1985-01-09|Pasteurellosis vaccines
    RU98101249A|1999-12-10|OMR26 ANTIGEN HAEMOPHYLUS INFLUENZAE
    Linggood et al.1963|The toxoiding of purified diphtheria toxin
    TW200540182A|2005-12-16|Altered fibronectin-binding protein of staphylococcus aureus
    JP6773830B2|2020-10-21|Immunogenic composition for use in treatment
    CA2282779A1|2000-03-21|Formulation comprising an antigen, an adjuvant and an amino acid for use in immunization.
    Relyveld et al.1983|[3] Preparation of vaccines by the action of glutaraldehyde on toxins, bacteria, viruses, allergens, and cells
    CA1066621A|1979-11-20|Dialdehyde treatment of tetanus toxin and derivative obtained
    US4247539A|1981-01-27|Hemagglutinin of Haemophilus gallinarum
    US4160023A|1979-07-03|Toxoids derived from protease and elastase of Pseudomonas aeruginosa and production thereof
    US4575459A|1986-03-11|Toxoids of elastase of Pseudomonas aeruginosa origin
    GB1560861A|1980-02-13|Toxoid derived from the elastase of pseudomonas aeruginosa and the production thereof
    FI62540B|1982-09-30|FOERFARANDE FOER FRAMSTAELLNING AV ELASTASTOXOID SOM ANVAENDS VID FRAMSTAELLNING AV MOT PSEUDOMONAS AERUGINOSA-INFEKTION VERKSAM TREKOMPONENTVACCIN
    GB1560862A|1980-02-13|Toxoid derived from the protease of pseudomonas aeruginosa and the production thereof
    Ecker et al.1932|Studies on the Adsorption of Diphtheria Toxin to and Elution from Magnesium Hydroxide
    Homma et al.1983|Effectiveness of immunization with multicomponent vaccines in protection against hemorrhagic pneumonia due to Pseudomonas aeruginosa infection in mink
    Maurer1958|ANTIGENICITY OF GELATIN: III. The Effect of Physical and Enzymatic Treatments of Gelatin on the Subsequent Precipitin Reaction
    RU2129014C1|1999-04-20|Method of preparing antibodies raised to diphtheria corynebacteria
    EP1247816A1|2002-10-09|Immunogen, antivenom and vaccine against the venom of the black widow spider
    Habermann et al.1975|Preparation, measurement and possible use of human antitoxin againstCl. botulinum A, B, and E toxins
    同族专利:
    公开号 | 公开日
    GB1546035A|1979-05-16|
    JPS6133010B2|1986-07-31|
    FR2340099A1|1977-09-02|
    FI770169A|1977-08-06|
    DE2704766C2|1988-06-16|
    US4157389A|1979-06-05|
    DK144753B|1982-06-01|
    NL7701266A|1977-08-09|
    FI62539C|1983-01-10|
    SE7701038L|1977-08-06|
    FI62539B|1982-09-30|
    DK49677A|1977-08-06|
    CA1082595A|1980-07-29|
    DK144753C|1982-10-25|
    FR2340099B1|1981-05-08|
    SE425213B|1982-09-13|
    JPS5296729A|1977-08-13|
    DE2704766A1|1977-08-11|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US2528972A|1947-05-15|1950-11-07|Western Reserve University|Prophylactic toxoid compound and method of making same|
    US3135662A|1961-01-05|1964-06-02|Burroughs Wellcome Co|Diphtheria toxoid preparation and its production|
    US3658986A|1969-07-02|1972-04-25|Victor N Tompkins|Immunization methods against toxic effects of bacterial infection|
    US3674863A|1969-12-08|1972-07-04|Parke Davis & Co|Polyvalent immunizing agents and methods for their production|
    DE2152112C3|1970-10-20|1979-10-11|Yuzuru Homma|Vaccine against Pseudomonas aeruginosa|
    US3987164A|1970-10-20|1976-10-19|Yuzuru Homma|Method for prevention of pseudomonas aeruginosa infections|
    US3928565A|1971-10-19|1975-12-23|Yuzuru Homma|Pharmaceutical preparation of pseudomonas aeruginosa bacterial component possessing anti-tumor and anti-infection properties|
    FR2227861B1|1973-05-04|1976-07-02|Anvar|
    DE2340911A1|1973-08-13|1975-05-07|Behringwerke Ag|TETANUS ANTIGEN AND PROCESS FOR ITS PRODUCTION|
    JPS6123167B2|1975-05-14|1986-06-04|Tokyo Daigaku|CA1085293A|1976-02-05|1980-09-09|Yuzuru Homma|Toxoids derived from protease and elastase of pseudomonas aeruginosa and production thereof|
    US4428931A|1982-03-15|1984-01-31|Merck & Co., Inc.|Bacterial toxoids and gram-negative immune globulin therefrom|
    HU188847B|1983-02-22|1986-05-28|Human Oltoanyagtermeloe Es Kutato Intezet,Hu|Process for producing liophylized combined vaccines|
    US4663160A|1983-03-14|1987-05-05|Miles Laboratories, Inc.|Vaccines for gram-negative bacteria|
    CA1256370A|1984-02-24|1989-06-27|Yuzuru Homma|Toxoids of elastase of pseudomonas aeruginosa origin|
    US4834976A|1986-07-03|1989-05-30|Genetic Systems Corporation|Monoclonal antibodies to pseudomonas aeruginosa flagella|
    US4772465A|1986-10-27|1988-09-20|Miles Laboratories, Inc.|Method of treating polymicrobial burn wound sepsis with a combination therapy of ciprofloxacin and pseudomonas immune globulin|
    US5233024A|1991-04-09|1993-08-03|The Brigham & Women's Hospital|Anti-idiotypic monoclonal antibodies for mucoid pseudomonas aeruginosa, their preparation and use|
    CN109929776A|2016-02-17|2019-06-25|中国农业科学院特产研究所|Bacterial strain and its application and vaccine and preparation method thereof|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    JP51010838A|JPS6133010B2|1976-02-05|1976-02-05|
    [返回顶部]